Percutaneous biopsy of renal masses: Sensitivity and negative predictive value stratified by clinical setting and size of masses

Frank J. Rybicki, Kirstin M. Shu, Edmund S. Cibas, Julia R. Fielding, Eric VanSonnenberg, Stuart G. Silverman

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

OBJECTIVE. The purpose of our retrospective study was to evaluate the sensitivity and negative predictive value of percutaneous biopsy of renal masses stratified by clinical setting and the size of the mass. MATERIALS AND METHODS. We categorized 115 consecutive percutaneous biopsies of renal masses in 113 patients into four clinical settings and three groups of mass sizes. The sensitivity and negative predictive value were computed (with 95% confidence intervals [CI]) for each clinical setting and for each size group. RESULTS. For all procedures (n = 115), the sensitivity and negative predictive value were 90% (95% CI, 81-95%) and 64% (95% CI, 44-81%), respectively. For patients with a known malignancy who presented with a renal mass (n = 55), the sensitivity and negative predictive value were 90% (95% CI, 78-96%) and 38% (95% CI, 10-74%), respectively. For patients with no known malignancy and suspected unresectable tumor (n = 36), the sensitivity and negative predictive value were 92% (95% CI, 76-98%) and 0%, respectively. For patients with no known malignancy who presented with a cystic mass (n = 16), the sensitivity and negative predictive value were 33% (95% CI, 2-87%) and 87% (95% CI, 58-98%), respectively. For patients who were not surgical candidates with a renal cell carcinoma (n = 8) that was thought to be resectable, both the sensitivity and negative predictive value were 100%. For masses 3 cm and less (n = 31), the sensitivity and negative predictive value were 84% (95% CI, 63-95%) and 60% (95% CI, 27-86%), respectively. For masses between 4 and 6 cm (n = 42), the sensitivity and negative predictive value were 97% (95% CI, 83-100%) and 89% (95% CI, 51-99%), respectively. For masses greater than 6 cm (n = 42), the sensitivity and negative predictive value were 87% (95% CI, 71-95%) and 44% (95% CI, 15-77%), respectively. CONCLUSION. Percutaneous renal mass biopsy has a high sensitivity in three clinical settings: patients with a known malignancy, patients with no known malignancy and suspected unresectable tumor, and nonsurgical patients with a mass suspected to be a resectable renal cell carcinoma. Negative results in small (≤ 3 cm) and large (> 6 cm) masses should be viewed with caution.

Original languageEnglish (US)
Pages (from-to)1281-1287
Number of pages7
JournalAmerican Journal of Roentgenology
Volume180
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

Confidence Intervals
Kidney
Biopsy
Neoplasms
Renal Cell Carcinoma
Retrospective Studies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Percutaneous biopsy of renal masses : Sensitivity and negative predictive value stratified by clinical setting and size of masses. / Rybicki, Frank J.; Shu, Kirstin M.; Cibas, Edmund S.; Fielding, Julia R.; VanSonnenberg, Eric; Silverman, Stuart G.

In: American Journal of Roentgenology, Vol. 180, No. 5, 01.05.2003, p. 1281-1287.

Research output: Contribution to journalArticle

Rybicki, Frank J. ; Shu, Kirstin M. ; Cibas, Edmund S. ; Fielding, Julia R. ; VanSonnenberg, Eric ; Silverman, Stuart G. / Percutaneous biopsy of renal masses : Sensitivity and negative predictive value stratified by clinical setting and size of masses. In: American Journal of Roentgenology. 2003 ; Vol. 180, No. 5. pp. 1281-1287.
@article{6e0e31ea3b874a5a96d7dd15ce954c2a,
title = "Percutaneous biopsy of renal masses: Sensitivity and negative predictive value stratified by clinical setting and size of masses",
abstract = "OBJECTIVE. The purpose of our retrospective study was to evaluate the sensitivity and negative predictive value of percutaneous biopsy of renal masses stratified by clinical setting and the size of the mass. MATERIALS AND METHODS. We categorized 115 consecutive percutaneous biopsies of renal masses in 113 patients into four clinical settings and three groups of mass sizes. The sensitivity and negative predictive value were computed (with 95{\%} confidence intervals [CI]) for each clinical setting and for each size group. RESULTS. For all procedures (n = 115), the sensitivity and negative predictive value were 90{\%} (95{\%} CI, 81-95{\%}) and 64{\%} (95{\%} CI, 44-81{\%}), respectively. For patients with a known malignancy who presented with a renal mass (n = 55), the sensitivity and negative predictive value were 90{\%} (95{\%} CI, 78-96{\%}) and 38{\%} (95{\%} CI, 10-74{\%}), respectively. For patients with no known malignancy and suspected unresectable tumor (n = 36), the sensitivity and negative predictive value were 92{\%} (95{\%} CI, 76-98{\%}) and 0{\%}, respectively. For patients with no known malignancy who presented with a cystic mass (n = 16), the sensitivity and negative predictive value were 33{\%} (95{\%} CI, 2-87{\%}) and 87{\%} (95{\%} CI, 58-98{\%}), respectively. For patients who were not surgical candidates with a renal cell carcinoma (n = 8) that was thought to be resectable, both the sensitivity and negative predictive value were 100{\%}. For masses 3 cm and less (n = 31), the sensitivity and negative predictive value were 84{\%} (95{\%} CI, 63-95{\%}) and 60{\%} (95{\%} CI, 27-86{\%}), respectively. For masses between 4 and 6 cm (n = 42), the sensitivity and negative predictive value were 97{\%} (95{\%} CI, 83-100{\%}) and 89{\%} (95{\%} CI, 51-99{\%}), respectively. For masses greater than 6 cm (n = 42), the sensitivity and negative predictive value were 87{\%} (95{\%} CI, 71-95{\%}) and 44{\%} (95{\%} CI, 15-77{\%}), respectively. CONCLUSION. Percutaneous renal mass biopsy has a high sensitivity in three clinical settings: patients with a known malignancy, patients with no known malignancy and suspected unresectable tumor, and nonsurgical patients with a mass suspected to be a resectable renal cell carcinoma. Negative results in small (≤ 3 cm) and large (> 6 cm) masses should be viewed with caution.",
author = "Rybicki, {Frank J.} and Shu, {Kirstin M.} and Cibas, {Edmund S.} and Fielding, {Julia R.} and Eric VanSonnenberg and Silverman, {Stuart G.}",
year = "2003",
month = "5",
day = "1",
doi = "10.2214/ajr.180.5.1801281",
language = "English (US)",
volume = "180",
pages = "1281--1287",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "5",

}

TY - JOUR

T1 - Percutaneous biopsy of renal masses

T2 - Sensitivity and negative predictive value stratified by clinical setting and size of masses

AU - Rybicki, Frank J.

AU - Shu, Kirstin M.

AU - Cibas, Edmund S.

AU - Fielding, Julia R.

AU - VanSonnenberg, Eric

AU - Silverman, Stuart G.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - OBJECTIVE. The purpose of our retrospective study was to evaluate the sensitivity and negative predictive value of percutaneous biopsy of renal masses stratified by clinical setting and the size of the mass. MATERIALS AND METHODS. We categorized 115 consecutive percutaneous biopsies of renal masses in 113 patients into four clinical settings and three groups of mass sizes. The sensitivity and negative predictive value were computed (with 95% confidence intervals [CI]) for each clinical setting and for each size group. RESULTS. For all procedures (n = 115), the sensitivity and negative predictive value were 90% (95% CI, 81-95%) and 64% (95% CI, 44-81%), respectively. For patients with a known malignancy who presented with a renal mass (n = 55), the sensitivity and negative predictive value were 90% (95% CI, 78-96%) and 38% (95% CI, 10-74%), respectively. For patients with no known malignancy and suspected unresectable tumor (n = 36), the sensitivity and negative predictive value were 92% (95% CI, 76-98%) and 0%, respectively. For patients with no known malignancy who presented with a cystic mass (n = 16), the sensitivity and negative predictive value were 33% (95% CI, 2-87%) and 87% (95% CI, 58-98%), respectively. For patients who were not surgical candidates with a renal cell carcinoma (n = 8) that was thought to be resectable, both the sensitivity and negative predictive value were 100%. For masses 3 cm and less (n = 31), the sensitivity and negative predictive value were 84% (95% CI, 63-95%) and 60% (95% CI, 27-86%), respectively. For masses between 4 and 6 cm (n = 42), the sensitivity and negative predictive value were 97% (95% CI, 83-100%) and 89% (95% CI, 51-99%), respectively. For masses greater than 6 cm (n = 42), the sensitivity and negative predictive value were 87% (95% CI, 71-95%) and 44% (95% CI, 15-77%), respectively. CONCLUSION. Percutaneous renal mass biopsy has a high sensitivity in three clinical settings: patients with a known malignancy, patients with no known malignancy and suspected unresectable tumor, and nonsurgical patients with a mass suspected to be a resectable renal cell carcinoma. Negative results in small (≤ 3 cm) and large (> 6 cm) masses should be viewed with caution.

AB - OBJECTIVE. The purpose of our retrospective study was to evaluate the sensitivity and negative predictive value of percutaneous biopsy of renal masses stratified by clinical setting and the size of the mass. MATERIALS AND METHODS. We categorized 115 consecutive percutaneous biopsies of renal masses in 113 patients into four clinical settings and three groups of mass sizes. The sensitivity and negative predictive value were computed (with 95% confidence intervals [CI]) for each clinical setting and for each size group. RESULTS. For all procedures (n = 115), the sensitivity and negative predictive value were 90% (95% CI, 81-95%) and 64% (95% CI, 44-81%), respectively. For patients with a known malignancy who presented with a renal mass (n = 55), the sensitivity and negative predictive value were 90% (95% CI, 78-96%) and 38% (95% CI, 10-74%), respectively. For patients with no known malignancy and suspected unresectable tumor (n = 36), the sensitivity and negative predictive value were 92% (95% CI, 76-98%) and 0%, respectively. For patients with no known malignancy who presented with a cystic mass (n = 16), the sensitivity and negative predictive value were 33% (95% CI, 2-87%) and 87% (95% CI, 58-98%), respectively. For patients who were not surgical candidates with a renal cell carcinoma (n = 8) that was thought to be resectable, both the sensitivity and negative predictive value were 100%. For masses 3 cm and less (n = 31), the sensitivity and negative predictive value were 84% (95% CI, 63-95%) and 60% (95% CI, 27-86%), respectively. For masses between 4 and 6 cm (n = 42), the sensitivity and negative predictive value were 97% (95% CI, 83-100%) and 89% (95% CI, 51-99%), respectively. For masses greater than 6 cm (n = 42), the sensitivity and negative predictive value were 87% (95% CI, 71-95%) and 44% (95% CI, 15-77%), respectively. CONCLUSION. Percutaneous renal mass biopsy has a high sensitivity in three clinical settings: patients with a known malignancy, patients with no known malignancy and suspected unresectable tumor, and nonsurgical patients with a mass suspected to be a resectable renal cell carcinoma. Negative results in small (≤ 3 cm) and large (> 6 cm) masses should be viewed with caution.

UR - http://www.scopus.com/inward/record.url?scp=0037405262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037405262&partnerID=8YFLogxK

U2 - 10.2214/ajr.180.5.1801281

DO - 10.2214/ajr.180.5.1801281

M3 - Article

C2 - 12704038

AN - SCOPUS:0037405262

VL - 180

SP - 1281

EP - 1287

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 5

ER -